MB-102 is a Gene-Modified Cell Therapy owned by Mustang Bio, and is involved in 3 clinical trials, which are ongoing.
MB-102 elicits immunostimulant effects. Interleukin-3 receptor alpha chain (CD123) is over expressed in cancers. The therapy by expressing chimeric antigen receptors redirects the T-cells to acute myeloid leukemia-associated antigens which recognize CD123 cells and destroy them.
The revenue for MB-102 is expected to reach a total of $88m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the MB-102 NPV Report.
MB-102 is under development for the treatment of relapsed or refractory acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm (natural killer cell lymphomas). The therapy is administered through intravenous route. It includes autologous T cells genetically modified to express CD123 specific hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor which targets different epitopes on CD123. The drug candidate was under development for high-risk myelodysplastic syndrome (MDS) and
Mustang Bio Overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
The operating loss of the company was US$66.7 million in FY2021, compared to an operating loss of US$56.8 million in FY2020. The net loss of the company was US$66.4 million in FY2021, compared to a net loss of US$60 million in FY2020.
Quick View – MB-102
|Highest Development Stage|